Context Therapeutics (CNTX) News Today $1.13 -0.08 (-6.61%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.06 (+4.87%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Average Price Target from BrokeragesOctober 7 at 2:27 AM | americanbankingnews.comContext Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingOctober 6 at 10:20 AM | finance.yahoo.comContext Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual MeetingOctober 6 at 7:50 AM | quiverquant.comQContext Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual MeetingOctober 6 at 7:30 AM | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from BrokeragesOctober 4 at 4:06 AM | marketbeat.comContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of Context Therapeutics (CNTX) with Overweight RecommendationOctober 3, 2025 | msn.comContext Therapeutics initiated with an Overweight at Cantor FitzgeraldOctober 2, 2025 | msn.comGuggenheim Initiates Coverage of Context Therapeutics (CNTX) with Buy RecommendationSeptember 19, 2025 | msn.comContext Therapeutics (NASDAQ:CNTX) Now Covered by GuggenheimSeptember 19, 2025 | marketbeat.comContext Therapeutics initiated with a Buy at GuggenheimSeptember 18, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateSeptember 15, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.comContext Therapeutics management to meet with MaximSeptember 10, 2025 | msn.comAlly Bridge Group NY LLC Has $708,000 Stock Position in Context Therapeutics Inc. $CNTXSeptember 5, 2025 | marketbeat.comContext Therapeutics Granted Nasdaq Extension for ComplianceSeptember 2, 2025 | tipranks.comAffinity Asset Advisors LLC Has $404,000 Stock Holdings in Context Therapeutics Inc. $CNTXAugust 28, 2025 | marketbeat.comContext Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comContext Therapeutics Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from BrokeragesAugust 16, 2025 | marketbeat.comWilliam Blair Has Pessimistic Outlook of CNTX Q3 EarningsAugust 11, 2025 | marketbeat.comContext Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2August 8, 2025 | msn.comHC Wainwright Lowers Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00August 8, 2025 | marketbeat.comContext Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral CapitalAugust 8, 2025 | marketbeat.comContext Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsAugust 6, 2025 | globenewswire.comContext Therapeutics (CNTX) to Release Earnings on WednesdayJuly 31, 2025 | marketbeat.comContext Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025July 25, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 21, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Buy" by BrokeragesJune 26, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Earns Overweight Rating from Piper SandlerJune 26, 2025 | marketbeat.comContext Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comContext Therapeutics Inc. (NASDAQ:CNTX) Insider Alex C. Levit Purchases 20,000 SharesJune 11, 2025 | insidertrades.comContext Therapeutics: Undervalued Cancer FighterJune 10, 2025 | seekingalpha.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) Insider Buys 20,000 Shares of StockJune 10, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) CFO Acquires $25,606.40 in StockJune 10, 2025 | marketbeat.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Buys 100,000 Shares of StockJune 10, 2025 | marketbeat.comContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingJune 2, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | finanznachrichten.deContext Therapeutics Inc. Appoints Dr. Karen Chagin as Chief Medical OfficerMay 29, 2025 | quiverquant.comQContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | globenewswire.comVelan Capital Investment Management LP Has $94,000 Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX)May 22, 2025 | marketbeat.comMPM Bioimpact LLC Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX)May 16, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by BrokeragesMay 15, 2025 | marketbeat.comWilliam Blair Has Positive Outlook of CNTX FY2025 EarningsMay 13, 2025 | marketbeat.comResearch Analysts Offer Predictions for CNTX Q2 EarningsMay 13, 2025 | marketbeat.comContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comContext Therapeutics Reports Q1 2025 Financial Results and Clinical ProgressMay 11, 2025 | msn.comD. Boral Capital Reiterates "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)May 10, 2025 | marketbeat.comCONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly EarningsMay 9, 2025 | nasdaq.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.170.54▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼82▲CNTX Articles Average Week Get the Latest News and Ratings for CNTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Context Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TKNO News CAPR News REPL News CGC News ALEC News MREO News UPXI News CADL News ALDX News SCPH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
